Bronchial anastomotic healing in canine lung allotransplants treated with cyclosporine.
Bronchial anastomotic healing was evaluated in 22 long-term-surviving canine lung allotransplant recipients treated with cyclosporine as the major immunosuppressive agent. Mean survival in these dogs was over 155 days, and 4 animals survived 1-3 years. Bronchial anastomotic complications were limited to 5 cases of minimal (less than 15%) bronchostenosis. The bronchial anastomoses became somewhat edematous and friable during rejection episodes, but no clinically serious sequelae--such as hemorrhage, peribronchial abscess, or bronchial dehiscence--were observed. Gross and microscopic evaluation of the recipient and donor segments of the anastomoses revealed excellent healing, with only scattered areas of inflammatory cells. The decreased frequency and severity of rejection episodes in animals treated with cyclosporine permits early revascularization of the bronchus to take place and reduces the need for other immunosuppressive agents that may interfere with bronchial healing. Cyclosporine is an effective immunosuppressive agent for canine lung allotransplantation and allows normal bronchial anastomotic healing to occur.
D000818:Animals; D001980:Bronchi / Q000187:drug effects / Q000473:pathology / Q000601:surgery*; D003524:Cyclosporins / Q000633:toxicity*; D004285:Dogs; D016040:Lung Transplantation; D014184:Transplantation, Homologous; D014945:Wound Healing / Q000187:drug effects*
D003524:Cyclosporins